| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 26 | 2009 | 1075 | 1.230 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 26 | 2019 | 2438 | 1.140 |
Why?
|
| Lung Neoplasms | 28 | 2009 | 2262 | 1.030 |
Why?
|
| Esophageal Neoplasms | 7 | 2010 | 321 | 0.690 |
Why?
|
| Paclitaxel | 14 | 2008 | 460 | 0.530 |
Why?
|
| Taxoids | 7 | 2010 | 129 | 0.430 |
Why?
|
| Sulfonamides | 2 | 2008 | 300 | 0.340 |
Why?
|
| Antineoplastic Agents, Phytogenic | 6 | 2008 | 276 | 0.330 |
Why?
|
| Leukemia, Lymphoid | 11 | 1987 | 72 | 0.320 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2010 | 1076 | 0.300 |
Why?
|
| Stomach Neoplasms | 2 | 2010 | 266 | 0.290 |
Why?
|
| Survival Rate | 12 | 2019 | 1863 | 0.290 |
Why?
|
| Antineoplastic Agents | 15 | 2008 | 2360 | 0.280 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2007 | 122 | 0.280 |
Why?
|
| Combined Modality Therapy | 13 | 2010 | 1686 | 0.280 |
Why?
|
| Interprofessional Relations | 1 | 2007 | 121 | 0.270 |
Why?
|
| Carboplatin | 8 | 2008 | 286 | 0.260 |
Why?
|
| Neoplasms | 9 | 2007 | 2898 | 0.250 |
Why?
|
| Quinazolines | 4 | 2008 | 220 | 0.250 |
Why?
|
| Clinical Trials as Topic | 5 | 2007 | 1169 | 0.250 |
Why?
|
| Aged | 33 | 2019 | 18415 | 0.240 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2019 | 236 | 0.230 |
Why?
|
| Adenocarcinoma | 3 | 2010 | 1169 | 0.220 |
Why?
|
| Aged, 80 and over | 15 | 2019 | 6509 | 0.220 |
Why?
|
| Biomedical Research | 1 | 2007 | 376 | 0.220 |
Why?
|
| Neoplasm Staging | 11 | 2010 | 1939 | 0.210 |
Why?
|
| Bone Marrow | 8 | 1998 | 435 | 0.210 |
Why?
|
| Leukemia | 6 | 1982 | 320 | 0.210 |
Why?
|
| Adult | 35 | 2010 | 25648 | 0.200 |
Why?
|
| Middle Aged | 33 | 2010 | 25028 | 0.200 |
Why?
|
| Capecitabine | 2 | 2019 | 96 | 0.190 |
Why?
|
| Drug Administration Schedule | 10 | 2009 | 916 | 0.190 |
Why?
|
| Fluorouracil | 4 | 2019 | 556 | 0.190 |
Why?
|
| Organoplatinum Compounds | 4 | 2005 | 94 | 0.190 |
Why?
|
| Camptothecin | 3 | 2008 | 189 | 0.180 |
Why?
|
| Male | 46 | 2016 | 40966 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2008 | 1961 | 0.180 |
Why?
|
| Humans | 75 | 2019 | 86644 | 0.180 |
Why?
|
| Female | 47 | 2019 | 44533 | 0.180 |
Why?
|
| Disease-Free Survival | 7 | 2019 | 1204 | 0.170 |
Why?
|
| Carcinoma, Small Cell | 3 | 2002 | 134 | 0.160 |
Why?
|
| Etoposide | 3 | 2008 | 196 | 0.160 |
Why?
|
| Neutrophils | 3 | 2016 | 307 | 0.160 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 1993 | 375 | 0.150 |
Why?
|
| Vascular Remodeling | 1 | 2016 | 21 | 0.140 |
Why?
|
| Mast Cells | 1 | 2016 | 92 | 0.140 |
Why?
|
| Neovascularization, Physiologic | 1 | 2016 | 133 | 0.140 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2016 | 77 | 0.130 |
Why?
|
| Methotrexate | 9 | 2019 | 249 | 0.130 |
Why?
|
| Survival Analysis | 6 | 2009 | 1538 | 0.130 |
Why?
|
| Cyclophosphamide | 8 | 2019 | 299 | 0.130 |
Why?
|
| Leucovorin | 2 | 2005 | 218 | 0.130 |
Why?
|
| Breast Neoplasms | 3 | 2019 | 2903 | 0.120 |
Why?
|
| Medical Oncology | 1 | 1998 | 359 | 0.120 |
Why?
|
| Doxorubicin | 7 | 2019 | 295 | 0.120 |
Why?
|
| Disease Progression | 6 | 2009 | 1531 | 0.120 |
Why?
|
| Maximum Tolerated Dose | 4 | 2008 | 270 | 0.120 |
Why?
|
| Treatment Outcome | 11 | 2019 | 7993 | 0.120 |
Why?
|
| Endothelial Cells | 1 | 2016 | 428 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2008 | 589 | 0.120 |
Why?
|
| Mitosis | 9 | 1978 | 153 | 0.100 |
Why?
|
| Agranulocytosis | 3 | 1984 | 20 | 0.100 |
Why?
|
| Infusions, Intravenous | 4 | 2005 | 429 | 0.100 |
Why?
|
| Deoxycytidine | 2 | 2009 | 237 | 0.100 |
Why?
|
| Hydroxyurea | 2 | 2008 | 239 | 0.100 |
Why?
|
| Brain Neoplasms | 4 | 2006 | 763 | 0.100 |
Why?
|
| Head and Neck Neoplasms | 3 | 2007 | 1052 | 0.090 |
Why?
|
| Neoplasm Metastasis | 6 | 2009 | 1056 | 0.090 |
Why?
|
| Child | 20 | 1998 | 6927 | 0.090 |
Why?
|
| Lymphoma | 3 | 1982 | 262 | 0.090 |
Why?
|
| Ifosfamide | 4 | 2003 | 49 | 0.090 |
Why?
|
| Prognosis | 11 | 2008 | 3679 | 0.090 |
Why?
|
| Cisplatin | 5 | 2010 | 612 | 0.080 |
Why?
|
| Child, Preschool | 14 | 1998 | 3612 | 0.080 |
Why?
|
| Cell Division | 4 | 1976 | 696 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2009 | 1313 | 0.080 |
Why?
|
| Eicosanoids | 1 | 2008 | 16 | 0.080 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2008 | 33 | 0.080 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2008 | 33 | 0.080 |
Why?
|
| Aging | 1 | 1993 | 691 | 0.080 |
Why?
|
| Cyclooxygenase 2 | 1 | 2008 | 100 | 0.080 |
Why?
|
| Vinblastine | 3 | 2002 | 108 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2007 | 79 | 0.070 |
Why?
|
| Infant | 13 | 1998 | 3047 | 0.070 |
Why?
|
| Bone Marrow Cells | 7 | 1976 | 253 | 0.070 |
Why?
|
| Pyrazoles | 1 | 2008 | 153 | 0.070 |
Why?
|
| Glutamates | 1 | 2007 | 89 | 0.070 |
Why?
|
| Cytarabine | 6 | 1982 | 218 | 0.070 |
Why?
|
| United States | 3 | 2008 | 6672 | 0.070 |
Why?
|
| Asparaginase | 4 | 1982 | 35 | 0.070 |
Why?
|
| Guanine | 1 | 2007 | 208 | 0.070 |
Why?
|
| Dacarbazine | 1 | 2006 | 102 | 0.070 |
Why?
|
| Tegafur | 1 | 2005 | 17 | 0.070 |
Why?
|
| Neuroblastoma | 3 | 1977 | 374 | 0.060 |
Why?
|
| Drug Therapy, Combination | 8 | 1982 | 894 | 0.060 |
Why?
|
| Uracil | 1 | 2005 | 72 | 0.060 |
Why?
|
| Prodrugs | 1 | 2004 | 46 | 0.060 |
Why?
|
| Dipeptides | 1 | 2004 | 46 | 0.060 |
Why?
|
| Carbazoles | 1 | 2004 | 51 | 0.060 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2004 | 153 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2019 | 468 | 0.060 |
Why?
|
| Confidence Intervals | 1 | 2003 | 229 | 0.060 |
Why?
|
| Biomarkers, Tumor | 2 | 2008 | 1464 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 5 | 1976 | 763 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 1801 | 0.050 |
Why?
|
| Age Factors | 3 | 2019 | 1851 | 0.050 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2002 | 69 | 0.050 |
Why?
|
| Thionucleotides | 1 | 2002 | 56 | 0.050 |
Why?
|
| Anaphylaxis | 1 | 1982 | 33 | 0.050 |
Why?
|
| Insurance, Liability | 1 | 1981 | 10 | 0.050 |
Why?
|
| Radiotherapy Dosage | 3 | 2001 | 468 | 0.050 |
Why?
|
| ErbB Receptors | 3 | 2009 | 485 | 0.050 |
Why?
|
| Bone Marrow Examination | 5 | 1987 | 48 | 0.050 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1981 | 47 | 0.050 |
Why?
|
| Research | 1 | 1981 | 253 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2008 | 2501 | 0.050 |
Why?
|
| Thymidine | 6 | 1982 | 59 | 0.050 |
Why?
|
| Tritium | 6 | 1982 | 133 | 0.050 |
Why?
|
| Cell Cycle | 2 | 1982 | 502 | 0.050 |
Why?
|
| Ceftizoxime | 1 | 1999 | 3 | 0.040 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 1999 | 14 | 0.040 |
Why?
|
| Cephalosporins | 1 | 1999 | 24 | 0.040 |
Why?
|
| Drug Combinations | 4 | 2005 | 224 | 0.040 |
Why?
|
| Administration, Oral | 3 | 2001 | 684 | 0.040 |
Why?
|
| Leukocyte Count | 2 | 1993 | 220 | 0.040 |
Why?
|
| Antiphospholipid Syndrome | 1 | 1999 | 20 | 0.040 |
Why?
|
| American Cancer Society | 1 | 1998 | 13 | 0.040 |
Why?
|
| Plasma Exchange | 1 | 1999 | 29 | 0.040 |
Why?
|
| Vincristine | 6 | 1982 | 111 | 0.040 |
Why?
|
| Karyotyping | 2 | 1993 | 250 | 0.040 |
Why?
|
| Esophagitis | 1 | 1998 | 42 | 0.040 |
Why?
|
| Kinetics | 5 | 1982 | 1513 | 0.040 |
Why?
|
| Blood Platelets | 2 | 2016 | 149 | 0.040 |
Why?
|
| Autoantibodies | 1 | 1999 | 267 | 0.040 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 1977 | 32 | 0.040 |
Why?
|
| Glycoproteins | 1 | 1999 | 234 | 0.040 |
Why?
|
| Adolescent | 11 | 1998 | 8981 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2008 | 348 | 0.040 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2016 | 6 | 0.040 |
Why?
|
| NADPH Oxidase 2 | 1 | 2016 | 20 | 0.040 |
Why?
|
| Comprehensive Health Care | 1 | 1996 | 13 | 0.040 |
Why?
|
| Matrix Metalloproteinases | 1 | 2016 | 28 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 1999 | 241 | 0.040 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2016 | 47 | 0.040 |
Why?
|
| Professional-Family Relations | 1 | 1996 | 48 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2016 | 79 | 0.040 |
Why?
|
| Receptors, CXCR4 | 1 | 2016 | 44 | 0.040 |
Why?
|
| Remission Induction | 2 | 2008 | 722 | 0.030 |
Why?
|
| Hindlimb | 1 | 2016 | 89 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 1996 | 156 | 0.030 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 1996 | 57 | 0.030 |
Why?
|
| Health Resources | 1 | 1996 | 76 | 0.030 |
Why?
|
| Critical Care | 1 | 1999 | 370 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2016 | 179 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2016 | 248 | 0.030 |
Why?
|
| Arteries | 1 | 2016 | 176 | 0.030 |
Why?
|
| Aneuploidy | 2 | 2007 | 55 | 0.030 |
Why?
|
| Monocytes | 1 | 2016 | 214 | 0.030 |
Why?
|
| T-Lymphocytes | 2 | 2016 | 1195 | 0.030 |
Why?
|
| Bone Neoplasms | 3 | 1987 | 322 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2001 | 165 | 0.030 |
Why?
|
| Area Under Curve | 2 | 2007 | 334 | 0.030 |
Why?
|
| Time Factors | 5 | 2010 | 5210 | 0.030 |
Why?
|
| Patient Care Team | 1 | 1996 | 280 | 0.030 |
Why?
|
| Logistic Models | 2 | 2008 | 1186 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 480 | 0.030 |
Why?
|
| Premedication | 2 | 2003 | 54 | 0.030 |
Why?
|
| Leukopenia | 1 | 1993 | 65 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 1996 | 394 | 0.030 |
Why?
|
| Autoradiography | 3 | 1982 | 69 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 1993 | 211 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2008 | 1197 | 0.030 |
Why?
|
| Acute Disease | 3 | 1982 | 826 | 0.030 |
Why?
|
| Blood Transfusion | 3 | 1984 | 157 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 1996 | 610 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 1971 | 265 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1578 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 1970 | 163 | 0.020 |
Why?
|
| Chloramphenicol | 1 | 1969 | 18 | 0.020 |
Why?
|
| Prednisone | 3 | 1982 | 258 | 0.020 |
Why?
|
| Risk | 3 | 1981 | 674 | 0.020 |
Why?
|
| Anemia, Aplastic | 1 | 1969 | 30 | 0.020 |
Why?
|
| Diseases in Twins | 1 | 1969 | 65 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2007 | 2767 | 0.020 |
Why?
|
| Cetuximab | 1 | 2009 | 113 | 0.020 |
Why?
|
| Histocytochemistry | 2 | 1987 | 130 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2008 | 90 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2008 | 131 | 0.020 |
Why?
|
| Celecoxib | 1 | 2008 | 31 | 0.020 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 1967 | 6 | 0.020 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 1967 | 2 | 0.020 |
Why?
|
| Microscopy, Electron | 2 | 1987 | 503 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2010 | 301 | 0.020 |
Why?
|
| DNA | 4 | 1982 | 1294 | 0.020 |
Why?
|
| Rhabdomyosarcoma | 2 | 1978 | 40 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 1920 | 0.020 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1987 | 112 | 0.020 |
Why?
|
| Recurrence | 3 | 1999 | 1139 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2009 | 384 | 0.020 |
Why?
|
| Splenectomy | 2 | 1982 | 82 | 0.020 |
Why?
|
| Blood Cell Count | 2 | 2001 | 79 | 0.020 |
Why?
|
| Pemetrexed | 1 | 2007 | 76 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 860 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 214 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 1987 | 286 | 0.020 |
Why?
|
| Hydrocortisone | 3 | 1973 | 298 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 1967 | 183 | 0.020 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2005 | 50 | 0.020 |
Why?
|
| Nervous System Neoplasms | 1 | 1985 | 11 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2007 | 526 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2008 | 712 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 999 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 927 | 0.020 |
Why?
|
| Pleural Effusion | 1 | 2004 | 45 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 859 | 0.020 |
Why?
|
| Drug Hypersensitivity | 1 | 2004 | 37 | 0.020 |
Why?
|
| Isoflurophate | 1 | 1964 | 3 | 0.020 |
Why?
|
| Phosphorus Isotopes | 1 | 1964 | 24 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2005 | 233 | 0.020 |
Why?
|
| Remission, Spontaneous | 3 | 1979 | 53 | 0.020 |
Why?
|
| Quality of Life | 2 | 2005 | 1585 | 0.020 |
Why?
|
| Sulfamethoxazole | 1 | 1984 | 2 | 0.020 |
Why?
|
| Environment, Controlled | 1 | 1984 | 8 | 0.020 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1984 | 17 | 0.020 |
Why?
|
| Hypotension | 1 | 2004 | 70 | 0.020 |
Why?
|
| Patient Isolation | 1 | 1984 | 11 | 0.020 |
Why?
|
| Granulocytes | 1 | 1984 | 37 | 0.020 |
Why?
|
| Trimethoprim | 1 | 1984 | 15 | 0.020 |
Why?
|
| Genetics, Medical | 1 | 1964 | 52 | 0.010 |
Why?
|
| Probability | 2 | 1982 | 355 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2005 | 407 | 0.010 |
Why?
|
| Isoantibodies | 2 | 1999 | 114 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 1753 | 0.010 |
Why?
|
| Neutropenia | 1 | 1964 | 215 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2009 | 930 | 0.010 |
Why?
|
| Biopsy | 1 | 1987 | 1163 | 0.010 |
Why?
|
| Bryostatins | 1 | 2003 | 15 | 0.010 |
Why?
|
| Lactones | 1 | 2003 | 28 | 0.010 |
Why?
|
| Macrolides | 1 | 2003 | 31 | 0.010 |
Why?
|
| Survival | 1 | 2002 | 21 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 1376 | 0.010 |
Why?
|
| Erwinia | 1 | 1982 | 2 | 0.010 |
Why?
|
| Mice | 1 | 2016 | 11352 | 0.010 |
Why?
|
| Genes, bcl-2 | 1 | 2002 | 16 | 0.010 |
Why?
|
| Exchange Transfusion, Whole Blood | 2 | 1972 | 18 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 1984 | 182 | 0.010 |
Why?
|
| United States Dept. of Health and Human Services | 1 | 1981 | 5 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 2001 | 141 | 0.010 |
Why?
|
| Liposomes | 1 | 2001 | 91 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2003 | 256 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 1982 | 235 | 0.010 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2001 | 33 | 0.010 |
Why?
|
| Safety | 1 | 2001 | 152 | 0.010 |
Why?
|
| Radiation Pneumonitis | 1 | 2001 | 21 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1982 | 679 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1982 | 464 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2003 | 352 | 0.010 |
Why?
|
| Morals | 1 | 1981 | 92 | 0.010 |
Why?
|
| Coombs Test | 1 | 1999 | 8 | 0.010 |
Why?
|
| Creatinine | 1 | 2001 | 338 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2001 | 751 | 0.010 |
Why?
|
| North America | 1 | 2000 | 180 | 0.010 |
Why?
|
| Hemolysis | 1 | 1999 | 61 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1982 | 666 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 2001 | 363 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2008 | 4214 | 0.010 |
Why?
|
| beta 2-Glycoprotein I | 1 | 1999 | 5 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 1 | 1999 | 87 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 683 | 0.010 |
Why?
|
| Gangrene | 1 | 1999 | 7 | 0.010 |
Why?
|
| Europe | 1 | 2000 | 309 | 0.010 |
Why?
|
| Scleroderma, Localized | 1 | 1999 | 9 | 0.010 |
Why?
|
| Hematoma, Subdural | 1 | 1999 | 23 | 0.010 |
Why?
|
| Escherichia coli | 1 | 1982 | 597 | 0.010 |
Why?
|
| Ethics, Medical | 1 | 1981 | 306 | 0.010 |
Why?
|
| Filgrastim | 1 | 1998 | 56 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1984 | 746 | 0.010 |
Why?
|
| Leg | 1 | 1999 | 137 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2002 | 592 | 0.010 |
Why?
|
| Fingers | 1 | 1999 | 68 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1999 | 293 | 0.010 |
Why?
|
| Wilms Tumor | 1 | 1977 | 38 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1998 | 138 | 0.010 |
Why?
|
| Antibodies | 1 | 1999 | 350 | 0.010 |
Why?
|
| Thorax | 1 | 1997 | 75 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 1977 | 92 | 0.010 |
Why?
|
| Ischemia | 1 | 1999 | 243 | 0.010 |
Why?
|
| Animals | 1 | 2016 | 26582 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 1997 | 227 | 0.010 |
Why?
|
| Osteosarcoma | 1 | 1977 | 158 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1998 | 1014 | 0.010 |
Why?
|
| Phenotype | 1 | 1982 | 2378 | 0.010 |
Why?
|
| Thrombosis | 1 | 1999 | 296 | 0.010 |
Why?
|
| Anticoagulants | 1 | 1999 | 408 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 1998 | 2380 | 0.010 |
Why?
|
| Nephrectomy | 1 | 1977 | 294 | 0.010 |
Why?
|
| Body Surface Area | 1 | 1995 | 36 | 0.010 |
Why?
|
| Phagocytosis | 2 | 1974 | 85 | 0.010 |
Why?
|
| Phagocyte Bactericidal Dysfunction | 1 | 1974 | 2 | 0.010 |
Why?
|
| Pediatrics | 1 | 1998 | 344 | 0.010 |
Why?
|
| Drug Antagonism | 1 | 1973 | 7 | 0.010 |
Why?
|
| Research Design | 1 | 1997 | 594 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 1999 | 977 | 0.010 |
Why?
|
| Bone Marrow Diseases | 2 | 1985 | 40 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 1973 | 177 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 1972 | 66 | 0.010 |
Why?
|
| Deoxyuridine | 1 | 1971 | 3 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1971 | 29 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1971 | 91 | 0.010 |
Why?
|
| Injections, Spinal | 2 | 1982 | 44 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 1998 | 3640 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 3362 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1971 | 261 | 0.010 |
Why?
|
| gamma-Globulins | 1 | 1967 | 16 | 0.000 |
Why?
|
| Circadian Rhythm | 1 | 1970 | 303 | 0.000 |
Why?
|
| Blood Group Antigens | 1 | 1967 | 17 | 0.000 |
Why?
|
| Medulloblastoma | 1 | 1967 | 36 | 0.000 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1967 | 48 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1972 | 2818 | 0.000 |
Why?
|
| Pedigree | 1 | 1967 | 966 | 0.000 |
Why?
|
| Pharmacogenetics | 1 | 1969 | 434 | 0.000 |
Why?
|
| Inflammation | 1 | 1970 | 920 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 1970 | 1458 | 0.000 |
Why?
|
| Mercaptopurine | 1 | 1982 | 53 | 0.000 |
Why?
|
| Meningeal Neoplasms | 1 | 1979 | 61 | 0.000 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 1978 | 15 | 0.000 |
Why?
|
| Orbital Neoplasms | 1 | 1978 | 17 | 0.000 |
Why?
|
| Ear Neoplasms | 1 | 1978 | 10 | 0.000 |
Why?
|
| Central Nervous System | 1 | 1979 | 151 | 0.000 |
Why?
|
| Facial Neoplasms | 1 | 1978 | 25 | 0.000 |
Why?
|
| Ear, Middle | 1 | 1978 | 24 | 0.000 |
Why?
|
| Testicular Neoplasms | 1 | 1979 | 105 | 0.000 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 1978 | 47 | 0.000 |
Why?
|
| Infusions, Parenteral | 1 | 1976 | 50 | 0.000 |
Why?
|
| Daunorubicin | 1 | 1976 | 78 | 0.000 |
Why?
|
| Sex Factors | 1 | 1979 | 1054 | 0.000 |
Why?
|
| Blood Bactericidal Activity | 1 | 1974 | 5 | 0.000 |
Why?
|
| Staphylococcus | 1 | 1974 | 24 | 0.000 |
Why?
|
| Candida albicans | 1 | 1974 | 32 | 0.000 |
Why?
|
| Alkaline Phosphatase | 1 | 1974 | 132 | 0.000 |
Why?
|
| Chemotaxis | 1 | 1974 | 72 | 0.000 |
Why?
|
| Cytoplasmic Granules | 1 | 1974 | 94 | 0.000 |
Why?
|
| Staining and Labeling | 1 | 1974 | 165 | 0.000 |
Why?
|
| Lysosomes | 1 | 1974 | 104 | 0.000 |
Why?
|
| Cytoplasm | 1 | 1974 | 281 | 0.000 |
Why?
|
| Leukocytes | 1 | 1974 | 202 | 0.000 |
Why?
|
| In Vitro Techniques | 1 | 1974 | 989 | 0.000 |
Why?
|
| Cell Nucleus | 1 | 1974 | 579 | 0.000 |
Why?
|